Concurrent chemoradiotherapy using cisplatin plus S-1, an oral fluoropyrimidine, followed by surgery for selected patients with stage III non-small cell lung cancer: A single-center feasibility study

Surgery Today

Volumn 41, Issue 11, 2011, Pages 1492-1497

  Maruyama, Riichiroh ^a,b   Hirai, Fumihiko ^a   Ondo, Kaoru ^a   Kometani, Takuro ^a   Hamatake, Motoharu ^a   Seto, Takashi ^a   Sugio, Kenji ^a   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Cisplatin; Induction chemoradiotherapy; Non small cell lung cancer; S 1; Stage III; Surgical resection

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DERMATITIS; ESOPHAGITIS; FATALITY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPOCALCEMIA; LEUKOCYTE COUNT; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PATIENT SELECTION; PERIOPERATIVE PERIOD; THROMBOCYTE COUNT; TREATMENT REFUSAL; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OXONIC ACID; PATIENT SELECTION; PNEUMONECTOMY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME;

EID: 84855168886     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-011-4509-z     Document Type: Article

References (16)

1. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86.
2. van Meerbeeck JP, Kramer GWPM, Van Schil PEY, Legrand C, Smit EF, Schramel F, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99: 442-50. (Pubitemid 47073567)
3. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30.
4. Segawa Y, Ueoka H, Kiura K, Kamei H, Tabata M, Sakae K, et al. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced nonsmall-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer 2000;82:104-11. (Pubitemid 30008967)
5. Ichinose Y, Nakai Y, Kudoh S, Semba H, Yoshida S, Nukiwa T, et al. Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004;10:4369-73. (Pubitemid 38878876)
6. Ichinose Y, Fukuyama Y, Asoh H, Ushijima C, Okamoto T, Ikeda J, et al. Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer. Ann Thorac Surg 2003;76:1810-4. (Pubitemid 37510481)
7. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57. (Pubitemid 26276346)
8. Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, et al. Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer 2009;101:225-31.
9. The Japan Lung Cancer Society (editor). General rules for clinical and pathological record of lung cancer. 6th ed. Tokyo: Kanehara; 2003.
10. Travis WD CT, Corrin B, Shimosato Y, Brambilla E; Collaborators from 14 Countries. World Health Organization. International histological classification of tumors. Histological typing of lung and pleural tumors. 3rd ed. Berlin: Springer; 1999.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
13. Thomas M, Rube C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III nonsmall-cell lung cancer. Lancet Oncol 2008;9:636-48.
14. Allen A M, Mentzer SJ, Yeap BY, Soto R, Baldini EH, Rabin MS, et al. Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 2008;112:1106-13. (Pubitemid 351304596)
15. Shrager J B. Mediastinoscopy: still the gold standard. Ann Thorac Surg 2010;89:S2084-9.
16. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive mediastinal staging of lung cancer: ACCP evidencebased clinical practice guidelines (2nd ed.). Chest 2007;132: 202S-20S. (Pubitemid 47502808)